Icahn School of Medicine at Mount Sinai

Contact
icahn.mssm.edu
+212 2416500

Icahn School of Medicine at Mount Sinai

One Gustave L. Levy Place
NY 10029-6574 New York City
USA
+212 2416500
icahn.mssm.edu
Contact
Profile News
Contact

About Icahn School of Medicine at Mount Sinai

Read more about Icahn School of Medicine at Mount Sinai
Facts about Icahn School of Medicine at Mount Sinai
  • Industry : Healthcare

News about Icahn School of Medicine at Mount Sinai

Icahn School of Medicine at Mount Sinai

20-Sep-2024 | science

Mind Over Microbiome: How Mental States Impact Gut Health

New research reveals brain-gut circuit regulating immunity through microbiome modulation

Read news
Icahn School of Medicine at Mount Sinai

29-May-2024 | science

Altering cellular interactions around amyloid plaques may offer novel Alzheimer’s treatment strategies

Innovative research from Mount Sinai also identifies new pathways for research

Read news
Icahn School of Medicine at Mount Sinai

25-Oct-2023 | science

Model can predict the evolution of new covid variants

Evolutionary information can support the design of targeted vaccines

Read news
Icahn School of Medicine at Mount Sinai

10-Mar-2016 | science

Researchers report insights into blood stem cells from engineered stem cells

Building upon previous work, researchers at the Icahn School of Medicine at Mount Sinai identified cells in the embryos of mice that are precursors to ...

Read news
Icahn School of Medicine at Mount Sinai

20-Jul-2015 | science

Genetic markers linking risk for type 2 diabetes and Alzheimer's identified

Certain patients with type 2 diabetes (T2D) may have specific genetic risk factors that put them at higher risk for developing Alzheimer's disease (AD), ...

Read news
Icahn School of Medicine at Mount Sinai

19-Jan-2015 | science

One punch to knock out flu

The fact that this year's flu shot is not a good match against this year's influenza strain is well known, and has happened before. But now researchers at ...

Read news
Icahn School of Medicine at Mount Sinai

14-May-2014 | science

A unique pathway for targeting new therapeutics for addiction treatment

A research team from the Friedman Brain Institute of the Icahn School of Medicine at Mount Sinai has published evidence that shows that subtle changes of ...

Read news
Icahn School of Medicine at Mount Sinai

26-Feb-2014 | science

Opioid abuse initiates specific protein interactions in neurons

RGS-9-2 protein affects not only addiction, but analgesic relief and tolerance

Read news
Show more news about Icahn School of Medicine at Mount Sinai

Here you will find Icahn School of Medicine at Mount Sinai

Last viewed contents

Frank-Starling_law_of_the_heart

Go to page
Simply resolving inflammation through the flick of a switch - Frankincense resin as an anti-inflammatory - without side effects?

Simply resolving inflammation through the flick of a switch - Frankincense resin as an anti-inflammatory - without side effects?

Go to page

Erbitux Significantly Increases Survival in 1st-Line Metastatic Colorectal Cancer Patients

Go to page

Genzyme's Lemtrada Approved by the FDA

Go to page
Biomass production by reverse citric acid cycle - Central metabolic pathway runs "backwards" at high carbon dioxide concentrations

Biomass production by reverse citric acid cycle - Central metabolic pathway runs "backwards" at high carbon dioxide concentrations

Go to page

Category:School_counseling

Go to page

Henry_H._Goddard

Go to page

Cyrenaic Pharmaceuticals Reports Improvement of Negative Symptoms and Cognition in Schizophrenia Patients Treated with CYR-101 - Data suggest the drug could address the most important unmet medical need in schizophrenia

Go to page

Subitec raises 4.5 m euros in second round financing

Go to page

Fresenius Kabi and Bayer Schering Pharma extend collaboration regarding HESylation Technology

Go to page

Williams_syndrome

Go to page

Study at ASCO shows Novartis drug Afinitor first to shrink SEGA brain tumors in children and adults with tuberous sclerosis - Phase II study shows meaningful reduction in brain tumor size in 75% of patients with subependymal giant cell astrocytomas (SEGAs) from baseline to six months

Go to page